Gemcitabine versus FOLFIRINOX in patients with advanced hENT1+ve pancreatic adenocarcinoma.

被引：1
|
作者：
Calegari, Maria Alessandra
Orlandi, Armando
Indellicati, Giulia
Martini, Maurizio
Cocomazzi, Alessandra
Bagala, Cinzia
Zurlo, Valeria
Di Dio, Carmela
Barile, Rosalba
Monterisi, Santa
Cassano, Alessandra
Astone, Antonio
Barone, Carlo
机构：
[1] Policlin Univ A Gemelli, UOC Oncol Med, Rome, Italy
[2] Policlin Univ A Gemelli, Ist Anat Patol, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e15295
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15295
引用
收藏
页数：1
相关论文
共 50 条
  • [31] THE HENT1 IMMUNOHISTOCHEMISTRY DIAGNOSTIC TEST IS PREDICTIVE OF GEMCITABINE OUTCOME IN PANCREATIC DUCTAL ADENOCARCINOMA
    Raponi, M.
    Isaacson, J.
    Hahn, H.
    Bartosiewicz, M.
    Magnusson, A.
    Lin, K.
    Rolfe, L.
    Allen, A.
    Picozzi, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 236 - 236
  • [32] Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine.
    Arlen, Aimee Ginsburg
    Cartwright, Thomas H.
    Wilfong, Lalan S.
    Hoverman, J. Russell
    Nelson, Greg C.
    Turnwald, Brian
    Beveridge, Roy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study
    Viaud, Juliette
    Brac, Clemence
    Artru, Pascal
    Le Pabic, Estelle
    Leconte, Berengere
    Bodere, Anais
    Pracht, Marc
    Le Sourd, Samuel
    Edeline, Julien
    Lievre, Astrid
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (06) : 692 - 696
  • [34] Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma.
    Kim, G. P.
    Foster, N. R.
    Salim, M.
    Flynn, P. J.
    Moore, D. F.
    Zon, R.
    Mowat, R. B.
    Wiesenfeld, M.
    McCullough, A. E.
    Alberts, S. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment (NCT03126435).
    Chen, Li-Tzong
    Su, Muh-Hwan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] FOLFIRINOX and Gemcitabine/nab-Paclitaxel Demonstrate Improved Survival in Locally Advanced Unresectable Pancreatic Adenocarcinoma
    Bednar, F.
    Ocuin, L.
    Steve, J.
    Zenati, M.
    Winters, S.
    Hogg, M.
    Bahary, N.
    Zeh, H., III
    Zureikat, A.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : S175 - S176
  • [37] Updated use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine
    Cartwright, Thomas H.
    Arlen, Aimee Ginsburg
    Wilfong, Lalan S.
    Harrell, Robyn K.
    Hoverman, J. Russell
    Beveridge, Roy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX
    Peterson, Shawn L.
    Husnain, Muhammad
    Pollack, Terri
    Pimentel, Agustin
    Loaiza-Bonilla, Arturo
    Westendorf-Overley, Colleen
    Ratermann, Kelley
    Anthony, Lowell
    Desimone, Philip
    Goel, Gaurav
    Kudrimoti, Mahesh
    Dineen, Sean
    Tzeng, Ching-Wei D.
    Hosein, Peter J.
    ANTICANCER RESEARCH, 2018, 38 (07) : 4035 - 4039
  • [39] Prognostic Value of hENT-1 in Patients with Resected Pancreatic Adenocarcinoma
    Lai, K. K.
    Tan, A.
    Kim, R. D.
    Jiang, J.
    Wang, Y.
    Rybicki, L. A.
    Liu, X.
    MODERN PATHOLOGY, 2010, 23 : 360A - 360A
  • [40] NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma.
    Kim, G. P.
    Oberg, A.
    Kabat, B.
    Sing, A.
    Hedrick, E.
    Campbell, D.
    Alberts, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 206S - 206S
12345